Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium

Nicolas Wentzensen, Elizabeth M Poole, Britton Trabert, Emily White, Alan A Arslan, Alpa V Patel, V Wendy Setiawan, Kala Visvanathan, Elisabete Weiderpass, Hans-Olov Adami, Amanda Black, Leslie Bernstein, Louise A Brinton, Julie Buring, Lesley M Butler, Saioa Chamosa, Tess V Clendenen, Laure Dossus, Renee Fortner, Susan M Gapstur, Mia M Gaudet, Inger T Gram, Patricia Hartge, Judith Hoffman-Bolton, Annika Idahl, Michael Jones, Rudolf Kaaks, Victoria Kirsh, Woon-Puay Koh, James V Lacey Jr, I-Min Lee, Eva Lundin, Melissa A Merritt, N Charlotte Onland-Moret, Ulrike Peters, Jenny N Poynter, Sabina Rinaldi, Kim Robien, Thomas Rohan, Dale P Sandler, Catherine Schairer, Leo J Schouten, Louise K Sjöholm, Sabina Sieri, Anthony Swerdlow, Anna Tjonneland, Ruth Travis, Antonia Trichopoulou, Piet A van den Brandt, Lynne Wilkens, Alicja Wolk, Hannah P Yang, Anne Zeleniuch-Jacquotte, Shelley S Tworoger, Nicolas Wentzensen, Elizabeth M Poole, Britton Trabert, Emily White, Alan A Arslan, Alpa V Patel, V Wendy Setiawan, Kala Visvanathan, Elisabete Weiderpass, Hans-Olov Adami, Amanda Black, Leslie Bernstein, Louise A Brinton, Julie Buring, Lesley M Butler, Saioa Chamosa, Tess V Clendenen, Laure Dossus, Renee Fortner, Susan M Gapstur, Mia M Gaudet, Inger T Gram, Patricia Hartge, Judith Hoffman-Bolton, Annika Idahl, Michael Jones, Rudolf Kaaks, Victoria Kirsh, Woon-Puay Koh, James V Lacey Jr, I-Min Lee, Eva Lundin, Melissa A Merritt, N Charlotte Onland-Moret, Ulrike Peters, Jenny N Poynter, Sabina Rinaldi, Kim Robien, Thomas Rohan, Dale P Sandler, Catherine Schairer, Leo J Schouten, Louise K Sjöholm, Sabina Sieri, Anthony Swerdlow, Anna Tjonneland, Ruth Travis, Antonia Trichopoulou, Piet A van den Brandt, Lynne Wilkens, Alicja Wolk, Hannah P Yang, Anne Zeleniuch-Jacquotte, Shelley S Tworoger

Abstract

Purpose: An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic subtype in the Ovarian Cancer Cohort Consortium (OC3).

Patients and methods: Among 1.3 million women from 21 studies, 5,584 invasive epithelial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other). By using competing-risks Cox proportional hazards regression stratified by study and birth year and adjusted for age, parity, and oral contraceptive use, we assessed associations for all invasive cancers by histology. Heterogeneity was evaluated by likelihood ratio test.

Results: Most risk factors exhibited significant heterogeneity by histology. Higher parity was most strongly associated with endometrioid (relative risk [RR] per birth, 0.78; 95% CI, 0.74 to 0.83) and clear cell (RR, 0.68; 95% CI, 0.61 to 0.76) carcinomas (P value for heterogeneity [P-het] < .001). Similarly, age at menopause, endometriosis, and tubal ligation were only associated with endometrioid and clear cell tumors (P-het ≤ .01). Family history of breast cancer (P-het = .008) had modest heterogeneity. Smoking was associated with an increased risk of mucinous (RR per 20 pack-years, 1.26; 95% CI, 1.08 to 1.46) but a decreased risk of clear cell (RR, 0.72; 95% CI, 0.55 to 0.94) tumors (P-het = .004). Unsupervised clustering by risk factors separated endometrioid, clear cell, and low-grade serous carcinomas from high-grade serous and mucinous carcinomas.

Conclusion: The heterogeneous associations of risk factors with ovarian cancer subtypes emphasize the importance of conducting etiologic studies by ovarian cancer subtypes. Most established risk factors were more strongly associated with nonserous carcinomas, which demonstrate challenges for risk prediction of serous cancers, the most fatal subtype.

Conflict of interest statement

Authors’ disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

© 2016 by American Society of Clinical Oncology.

Figures

Fig 1.
Fig 1.
Unsupervised hierarchical clustering of ovarian cancer histologic subtypes by their associations with risk factors. Unsupervised hierarchical clustering of the (A) four subtypes and (B) that includes the serous subtype divided into well-, moderately, and poorly differentiated carcinomas by using β-estimates, complete linkage, and an uncentered correlation similarity metric. The categories used in the cluster analysis were ever versus never parous, ever versus never oral contraceptive (OC) use, ever versus never tubal ligation, ever versus never endometriosis, age at menarche > 15 v ≤ 11 years, age at menopause < 40 versus 50 to 55 years, ever versus never menopausal hormone therapy use, ever versus never hysterectomy, family history of breast cancer (yes v no), family history of ovarian cancer (yes v no), body mass index (BMI) > 35 versus 20 to 25 kg/m2, height (per 5-cm increase), and ever versus never smoking. The color scale shows the range of β-values for each exposure.

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
    1. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–2303.
    1. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet. 2016;387:945–956.
    1. Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia. Lancet. 1971;2:163.
    1. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459–1467.
    1. Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses’ Health Studies. Fertil Steril. 2014;102:192–198.
    1. Trabert B, Ness RB, Lo-Ciganic WH, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014;106:djt431.
    1. Jarboe EA, Folkins AK, Drapkin R, et al. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 2009;55:619.
    1. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol. 2011;42:918–931.
    1. Steffensen KD, Waldstrøm M, Grove A, et al. Improved classification of epithelial ovarian cancer: Results of 3 Danish cohorts. Int J Gynecol Cancer. 2011;21:1592–1600.
    1. Collaborative Group on Epidemiological Studies of Ovarian Cancer Ovarian cancer and body size: Individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012;9:e1001200.
    1. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–314.
    1. Beral V, Gaitskell K, Hermon C, et al. Ovarian cancer and smoking: Individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946–956.
    1. Beral V, Gaitskell K, Hermon C, et al. Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385:1835–1842.
    1. Fortner RT, Ose J, Merritt MA, et al. Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. Int J Cancer. 2015;137:1196–1208.
    1. Gates MA, Rosner BA, Hecht JL, et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171:45–53.
    1. Yang HP, Trabert B, Murphy MA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer. 2012;131:938–948.
    1. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51:524–532.
    1. Olsen CM, Nagle CM, Whiteman DC, et al. Obesity and risk of ovarian cancer subtypes: Evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer. 2013;20:251–262.
    1. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Lancet Oncol. 2012;13:385–394.
    1. Schouten LJ, Rivera C, Hunter DJ, et al. Height, body mass index, and ovarian cancer: A pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2008;17:902–912.
    1. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344:1250–1254.
    1. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: Have they different risk factors. J Clin Oncol. 2013;31:2607–2618.
    1. Newcomb PA, Storer BE, Marcus PM. Cigarette smoking in relation to risk of large bowel cancer in women. Cancer Res. 1995;55:4906–4909.
    1. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103:250–263.
    1. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
    1. Köbel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 2014;64:1004–1013.
    1. Matsuno RK, Sherman ME, Visvanathan K, et al. Agreement for tumor grade of ovarian carcinoma: Analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository. Cancer Causes Control. 2013;24:749–757.
    1. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267–282.
    1. Kotsopoulos J, Terry KL, Poole EM, et al. Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. Int J Cancer. 2013;133:730–739.
    1. Poole EM, Merritt MA, Jordan SJ, et al. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol Biomarkers Prev. 2013;22:429–437.
    1. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
    1. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198–5208.
    1. Schildkraut JM, Iversen ES, Akushevich L, et al. Molecular signatures of epithelial ovarian cancer: Analysis of associations with tumor characteristics and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev. 2013;22:1709–1721.
    1. Levine DA, Karlan BY, Strauss JF III: Evolving approaches in research and care for ovarian cancers: A report from the National Academies of Sciences, Engineering, and Medicine. JAMA, 315:1943-1944, 2016.
    1. Trabert B, Pinto L, Hartge P, et al. Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial. Gynecol Oncol. 2014;135:297–304.
    1. Trabert B, Brinton LA, Anderson GL, et al: Circulating estrogens and postmenopausal ovarian cancer risk in the Women’s Health Initiative Observational Study. Cancer Epidemiol Biomarkers Prev, 10.1158/1055-9965.EPI-15-1272-T [epub ahead of print on February 5, 2016]
    1. Pfeiffer RM, Park Y, Kreimer AR, et al. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: Derivation and validation from population-based cohort studies. PLoS Med. 2013;10:e1001492.

Source: PubMed

3
订阅